Medications for Hypereosinophilic Syndrome
8 results
Imatinib mesylate (imatinib mesylate)
(IMATINIB MESYLATE)Camber Pharmaceuticals, Inc.
Usage: This drug is indicated for treating newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)BluePoint Laboratories
Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Archis Pharma LLC
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Qilu Pharmaceutical Co., Ltd.
Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Wockhardt USA LLC.
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in blast crisis or after interferon failure, adult relapsed/refractory Philadelphia positive acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases with PDGFR rearrangements, aggressive systemic mastocytosis without D816V c-Kit mutation, hypereosinophilic syndrome, and unresectable dermatofibrosarcoma protuberans.
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)American Health Packaging
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML in various phases post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) in adults, and newly diagnosed Ph+ ALL in pediatric patients, among other specific malignancies.
Imatinib mesylate (imatinib)
(imatinib)Mylan Pharmaceuticals Inc.
Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
Nucala (mepolizumab)
(mepolizumab)GlaxoSmithKline LLC
Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma with eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients 12 years and older. It is not for acute bronchospasm relief.